Jennifer Stolin, MD
Family Medicine · Summerville, SCNPI 1710274295
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,750 of the $58,791 with a category attached, or 62.5%. ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) accounts for 83.8% of it on its own, with 45 other manufacturers making up the rest. Reporting peaked in 2024 at $34,361 and has fallen 57.6% since, to $14,579 in 2025. Among family medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 683 payments — averaging $86.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$49K
- Sunovion Pharmaceuticals Inc.$2K
- AbbVie$1K
- Lilly USA, LLC$906
- Otsuka America Pharmaceutical, Inc.$592
- E.r. Squibb & Sons, L.L.C.$550
- plus $5K from 40 others
What the payments were for
- Consulting fees$5,98510%
- Speaking & faculty fees$36,75063%
- Travel & lodging$4,1487%
- Food & beverage$11,81820%
- Education$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$58,791 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 66 | $69,924 |
| CaplytaLumateperone Tosylate | 23 | $42,704 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $39,383 |
| XareltoRivaroxaban | 26 | $39,294 |
| JardianceEmpagliflozin | 23 | $36,355 |
| EliquisApixaban | 22 | $23,424 |
| MyrbetriqMirabegron | 19 | $18,578 |
| MounjaroTirzepatide | 15 | $17,418 |
| TrulicityDulaglutide | 11 | $16,960 |
| JanuviaSitagliptin Phosphate | 13 | $16,633 |
| GemtesaVibegron | 20 | $15,649 |
| BelsomraSuvorexant | 19 | $9,134 |
| Duloxetine Hcl | 133 | $3,193 |
| Atorvastatin Calcium | 277 | $2,604 |
| Bupropion XlBupropion Hcl | 81 | $1,997 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $271 | $69,92466 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $49,286 | $42,70423 claims |
| GSKTrelegy Ellipta | $175 | $39,38333 claims |
| Johnson & JohnsonXarelto | $111 | $39,29426 claims |
| Boehringer IngelheimJardiance | $98 | $36,35523 claims |
| Lilly USA, LLCMounjaro, Trulicity, Olanzapine | $906 | $35,65056 claims |
| MerckJanuvia, Belsomra | $87 | $25,76632 claims |
| PfizerEliquis | $149 | $23,42422 claims |
| Astellas Pharma US IncMyrbetriq | $29 | $18,57819 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $331 | $15,64920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Summerville
- Jan BurgerSummerville$16K
- Stephen BruntonWinnsboro$1.3M
- Richard WilkesMt Pleasant$216K
- Andrew MartinColumbia$205K
- Ada StewartColumbia$186K
- Jeffrey BroderNorth Augusta$140K
- Terry NagelColumbia$112K
- Katherine JohnsonGreenwood$80K
- Scott SmithMount Pleasant$68K
- Nicholas PenningsNorth Myrtle Beach$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.